GlaxoSmithKline revealed sales of a key treatment against a potential flu pandemic have rocketed since January – on the day a new outbreak of bird flu was confirmed in the UK.

GlaxoSmithKline has reported a 14% rise in pre-tax profits to £6.7bn (€9.88bn) despite a 40% fall in sales of bestselling antidepressant Paxil.